Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Schizophrenia and other psychotic disorders

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44412   clinical trials with a EudraCT protocol, of which   7421   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    86 result(s) found for: Schizophrenia and other psychotic disorders. Displaying page 1 of 5.
    1  2  3  4  5  Next»
    EudraCT Number: 2009-011343-39 Sponsor Protocol Number: RIS-SCH-4226 Start Date*: 2009-06-15
    Sponsor Name:Janssen-Cilag AB
    Full Title: Patient and physician preferences and satisfaction with oral and long-acting injectable long-term antipsychotic treatment for psychotic disorders
    Medical condition: Schizophrenia, schizoaffective disorder, delusional disorder, psychotic disorder NOS or any other psychotic disorder patients demanding long term antipsychotic treatment
    Disease: Version SOC Term Classification Code Term Level
    9.1 10037253 Psychotic disorder NOS LLT
    9.1 10061920 Psychotic disorder LLT
    9.1 10039628 Schizophrenia and other psychotic disorders HLGT
    9.1 10012256 Delusional disorders HLT
    9.1 10039621 Schizoaffective disorder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: View results
    EudraCT Number: 2019-000470-36 Sponsor Protocol Number: SEP361-301 Start Date*: Information not available in EudraCT
    Sponsor Name:Sunovion Pharmaceuticals Inc.
    Full Title: A Randomized, Double-blind, Parallel-group, Placebo-controlled, Fixed-dose, Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in Acutely Psychotic Subjects with Schizophrenia
    Medical condition: Schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004873 10001064 Acute schizophrenia LLT
    20.0 100000004873 10008525 Childhood schizophrenia LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-000709-36 Sponsor Protocol Number: 15/0947 Start Date*: 2016-11-23
    Sponsor Name:UCL
    Full Title: Research into Antipsychotic Discontinuation and Reduction (RADAR): A Randomised Controlled Trial
    Medical condition: Schizophrenia, delusional disorders, schizoaffective disorder, psychosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10039626 Schizophrenia PT
    20.0 10037175 - Psychiatric disorders 10012256 Delusional disorders HLT
    20.0 10037175 - Psychiatric disorders 10039621 Schizoaffective disorder PT
    20.0 10037175 - Psychiatric disorders 10037234 Psychosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2019-000697-37 Sponsor Protocol Number: SEP361-302 Start Date*: 2019-09-06
    Sponsor Name:Sunovion Pharmaceuticals Inc.
    Full Title: A Randomized, Double-blind, Parallel-group, Placebo-controlled, Fixed-dose, Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in Acutely Psychotic Subjects with Schizophrenia
    Medical condition: Schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004873 10001064 Acute schizophrenia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: LV (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2013-000240-26 Sponsor Protocol Number: CBD_ADD_IN Start Date*: 2013-10-29
    Sponsor Name:King's College London [...]
    1. King's College London
    2. South London and Maudsley NHS Foundation Trust
    Full Title: Cannabidiol as an add-on therapy in treatment-refractory psychotic disorders
    Medical condition: Schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    16.1 10037175 - Psychiatric disorders 10039628 Schizophrenia and other psychotic disorders HLGT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-002713-35 Sponsor Protocol Number: AXCT01-01-03-2013 Start Date*: 2014-07-29
    Sponsor Name:MediPsych SA
    Full Title: Randomized, controlled trial of the effectiveness of add-on tolcapone to usual antipsychotic therapy on cognitive and negative symptoms of patients with schizophrenia genotyped for COMT polymorphisms
    Medical condition: schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    16.1 10037175 - Psychiatric disorders 10039628 Schizophrenia and other psychotic disorders HLGT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-000053-27 Sponsor Protocol Number: MELIA Start Date*: 2020-07-09
    Sponsor Name:UMC Utrecht
    Full Title: The MEtformin-LIfestyle in Antipsychotic users trial (MELIA): optimizing the use of metformin in the management of antipsychotic-induced weight gain.
    Medical condition: Antipsychotic-induced weight gain (AiWG)
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-001555-41 Sponsor Protocol Number: SEP361-201 Start Date*: 2016-10-27
    Sponsor Name:SUNOVION PHARMACEUTICALS INC.
    Full Title: A 4-Week, Randomized, Double-blind, Parallel-group, Placebo-controlled, Flexibly-dosed, Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in Acutely Psychotic Adult Subjects With ...
    Medical condition: Schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    19.0 10037175 - Psychiatric disorders 10039628 Schizophrenia and other psychotic disorders HLGT
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: View results
    EudraCT Number: 2022-000581-17 Sponsor Protocol Number: CVL-231-2002 Start Date*: 2022-10-18
    Sponsor Name:Cerevel Therapeutics, LLC
    Full Title: A Phase 2, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Two Fixed Doses (15 mg and 30 mg QD) of CVL-231 in Participants With Schizophreni...
    Medical condition: Patients with schizophrenia who are experiencing an acute exacerbation of psychosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10039628 Schizophrenia and other psychotic disorders HLGT
    20.0 10037175 - Psychiatric disorders 10039626 Schizophrenia PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2022-000580-52 Sponsor Protocol Number: CVL-231-2001 Start Date*: 2022-11-02
    Sponsor Name:Cerevel Therapeutics, LLC
    Full Title: A Phase 2, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Two Fixed Doses (10 mg and 30 mg QD) of CVL-231 in Participants With Schizophreni...
    Medical condition: Patients with schizophrenia who are experiencing an acute exacerbation of psychosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10039628 Schizophrenia and other psychotic disorders HLGT
    20.0 10037175 - Psychiatric disorders 10039626 Schizophrenia PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BG (Completed)
    Trial results: View results
    EudraCT Number: 2019-000696-16 Sponsor Protocol Number: SEP361-303 Start Date*: 2019-09-06
    Sponsor Name:Sunovion Pharmaceuticals Inc.
    Full Title: An Open-label Extension Study to Assess the Safety and Tolerability of SEP-363856 in Subjects with Schizophrenia
    Medical condition: Schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004873 10001064 Acute schizophrenia LLT
    20.0 100000004873 10008525 Childhood schizophrenia LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: LV (Completed) BG (Completed) HR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-000212-22 Sponsor Protocol Number: GWAP1241 Start Date*: 2013-12-13
    Sponsor Name:GW Research Ltd
    Full Title: A double-blind, randomised, placebo-controlled, parallel group study of GWP42003 as adjunctive therapy in the first line treatment of schizophrenia or related psychotic disorder
    Medical condition: Schizophrenia or related psychotic disorder
    Disease: Version SOC Term Classification Code Term Level
    14.1 10037175 - Psychiatric disorders 10039626 Schizophrenia PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) PL (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2018-004893-84 Sponsor Protocol Number: CBD-P Start Date*: 2019-08-22
    Sponsor Name:Mental Health Center Glostrup
    Full Title: Cannabidiol for treatment of non-affective psychosis and cannabis use
    Medical condition: Non-affective psychosis and lifetime cannabis use
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004873 10037234 Psychosis LLT
    21.1 100000004869 10070996 Cannabis use LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2009-016715-38 Sponsor Protocol Number: TEAprotocolversion3-12102009FINAL Start Date*: 2010-02-08
    Sponsor Name:University of Copenhagen
    Full Title: The TEA Trial- Tolerance and Effect of Antipsychotics in children and adolescents with psychosis An investigator-initiated, phase IV, randomised double-blind multi-centre trial of the benefits and...
    Medical condition: non-organic and non-drug-induced psychosis, meeting the criteria for ICD-10 diagnoses: F20, F22-F29 and F30.2, F31.2, F31.5, F32.3 and F33.3.
    Disease: Version SOC Term Classification Code Term Level
    16.1 10037175 - Psychiatric disorders 10032314 Other nonorganic psychoses LLT
    16.1 10037175 - Psychiatric disorders 10039626 Schizophrenia PT
    16.1 10037175 - Psychiatric disorders 10004916 Bipolar affective disorder, depressed, severe degree, specified as with psychotic behavior LLT
    16.1 10037175 - Psychiatric disorders 10025460 Major depressive disorder, recurrent episode, severe degree, specified as with psychotic behaviour LLT
    16.1 10037175 - Psychiatric disorders 10039621 Schizoaffective disorder PT
    16.1 10037175 - Psychiatric disorders 10025468 Major depressive disorder, single episode, severe degree, specified as with psychotic behavior LLT
    16.1 10037175 - Psychiatric disorders 10046122 Unspecified psychosis LLT
    16.1 10037175 - Psychiatric disorders 10026780 Manic psychosis LLT
    16.1 10037175 - Psychiatric disorders 10012255 Delusional disorder, unspecified type PT
    16.1 10037175 - Psychiatric disorders 10051988 Acute and transient psychotic disorder LLT
    16.1 10037175 - Psychiatric disorders 10004924 Bipolar affective disorder, manic, severe degree, specified as with psychotic behavior LLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-019897-33 Sponsor Protocol Number: 2522518514 Start Date*: 2011-04-14
    Sponsor Name:erasmus mc
    Full Title: Selective D1 activation by addition of L-Dopa to antipsychotic treatment in patients with schizophrenia
    Medical condition: patients with psychotic symptoms, diagnosed with schizophrenia
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-004504-35 Sponsor Protocol Number: RF-2010-2311148 Start Date*: 2013-02-26
    Sponsor Name:IRCCS CENTRO SAN GIOVANNI DI DIO FATEBENEFRATELLI
    Full Title: The use of Oxytocin as adjunctive therapy for the treatment of schizophrenia: a randomized, double blind trial
    Medical condition: Schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    14.1 10037175 - Psychiatric disorders 10039628 Schizophrenia and other psychotic disorders HLGT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-001278-44 Sponsor Protocol Number: CLZ_TRS_TEA Start Date*: 2021-05-26
    Sponsor Name:Fundación Hospital Provincial de Castellón
    Full Title: Comparative analysis of the effectiveness of clozapine in resistant schizophrenia and schizoafective disorder.
    Medical condition: Treatment-resistant schizophrenia and schizoafective disorder
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-006151-20 Sponsor Protocol Number: D1449L00029 Start Date*: 2006-08-29
    Sponsor Name:University of Erlangen-Nuremberg
    Full Title: Quetiapine and the dopaminergic epigenetic control – a pilot study
    Medical condition: Patients suffering from schizophrenia (ICD10: F20.x) Healthy controls
    Disease: Version SOC Term Classification Code Term Level
    8.1 10039628 Schizophrenia and other psychotic disorders HLGT
    Population Age: Adults Gender: Male
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-002176-83 Sponsor Protocol Number: SNP-S-01 Start Date*: 2015-04-01
    Sponsor Name:Clinirx Tangent Research
    Full Title: A randomized trial administering Sodium Nitroprusside vs. placebo as add-on to antipsychotics in patients with schizophrenia
    Medical condition: schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    17.1 10037175 - Psychiatric disorders 10039626 Schizophrenia PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: RO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-001337-40 Sponsor Protocol Number: BXCL501-105 Start Date*: 2021-10-05
    Sponsor Name:BioXcel Therapeutics, Inc.
    Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO DETERMINE EFFICACY AND SAFETY OF BXCL501 IN AGITATION ASSOCIATED WITH PEDIATRIC SCHIZOPHRENIA AND BIPOLAR DISORDER
    Medical condition: Subject that meets DSM-5 criteria for schizophrenia, schizoaffective, or schizophreniform disorder, or other specified/unspecified schizophrenia spectrum and/or other psychotic disorders OR Subjec...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10039628 Schizophrenia and other psychotic disorders HLGT
    20.0 10037175 - Psychiatric disorders 10039629 Schizophrenia childhood LLT
    21.1 10037175 - Psychiatric disorders 10057667 Bipolar disorder PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Restarted)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Oct 16 08:38:33 CEST 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA